microdosing glp-1 research People Are Weight-Loss Drugs Such as Ozempic and Wegovy. Here's Why What should you know before

The STEP 1 extension data showed maintained weight loss at 104 weeks, with participants maintaining an average 13.7% weight reduction from baseline

Within the black box, the FDA explains that the medications cause rodents to develop thyroid C-cell tumors, but that it is unknown whether the same occurs in humans

Francesco Giorgino, MD, an investigator on the ACHIEVE-5 trial, offered a longer-term perspective on orforgliprons potential in an interview published by Medscape Medical News, noting that its small-molecule structure makes it significantly easier to manufacture than peptide-based GLP-1 drugs

2018;137(23):e821e841

Glucagon-like peptide-1 (GLP-1) agonists are injectable weight loss drugs that help people feel fuller and eat less food, leading to weight loss

The stomach acid and digestive enzymes broke down peptides before much could be absorbed by the bloodstream